⚔️ Head-to-head
CJC-1295 vs Ipamorelin
Pep lines up the two side by side — verdict, mechanism, and the dimensions that actually differ — so you can see where each one wins.
By MrPepTalks Editorial · Updated 2026-07-06
CJC-1295
CJC1295 · Mod GRF 1-29
unproven🏆 Wins on human evidence grade
Ipamorelin
NNC 26-0161
unproven🏆 Wins on selectivity / off-target profile
CJC-1295
Dimension
Ipamorelin
A synthetic analog of growth-hormone-releasing hormone (GHRH). Some versions add a Drug Affinity Complex (DAC) that binds albumin and extends how long it stays active in the body.
What it is
A selective growth-hormone secretagogue that acts on the ghrelin receptor (GHS-R). It is one of the more selective peptides in its class in the research literature.
Works on the GHRH receptor in the pituitary, commonly researched for a sustained rise in growth-hormone signalling. Think of it as turning up the baseline signal.
Mechanism (the key difference)
Works on the ghrelin / GHS-R pathway, commonly researched for pulse-like releases of growth hormone. A different receptor and a different release pattern than a GHRH analog.
Studied in the context of growth-hormone and IGF-1 signalling; people report interest for recovery and body-composition goals. Effects in humans for those goals are still being studied.
What it's commonly researched for
Studied for growth-hormone release with a reputation for selectivity; people report interest for recovery and sleep-adjacent goals. Effects in humans for those goals are still being studied.
Grade B/C. Early human pharmacokinetic work measured how long the compound stayed active and tracked growth-hormone markers, but controlled outcome trials in healthy people are limited.
🏆 winner
Human evidence grade
Grade C. Most of the record is preclinical and mechanistic; well-controlled human outcome trials are scarce, so its human picture is thinner than CJC-1295's.
As a GHRH analog it mainly engages the GHRH pathway; the DAC version's long activity window is the main talking point in the literature.
Selectivity / off-target profile
Frequently described as selective, with less reported impact on cortisol and prolactin than older peptides in its class. Selectivity is the headline reason people bring it up.
🏆 winner
Commonly reported: water retention, tingling or numbness, flushing, headache, and local reactions at the study contact point. The longer-acting DAC version raises questions about a sustained rather than pulse-like signal, which the literature has flagged as worth watching.
Reported side effects
Commonly reported: headache, flushing, lightheadedness, and local reactions at the study contact point. Its selectivity is often framed as a gentler reported profile, but human safety data is limited, so that framing is not settled.
Provides the GHRH-side signal. On its own it is one half of the two-receptor idea people describe.
Why people pair them
Provides the ghrelin-side signal. Because the two act on different receptors, forums describe combining them for a complementary effect rather than picking one over the other.
Not FDA-approved. Sold for laboratory research use only, not for human use; it has not been proven safe or effective in people.
Regulatory status
Not FDA-approved. Sold for laboratory research use only, not for human use; it has not been proven safe or effective in people.
As with any research-grade peptide, the thing that actually varies between vendors is quality control: whether third-party purity and identity testing is published. That is a sourcing question, not an efficacy claim.
Sourcing reality
Same sourcing reality. Gray-market supply can carry contamination, endotoxins, or an identity that does not match the label, and none of that is visible in the vial.
CJC-1295 data sheetThe terse reference: facts, forms, and Pep's verdict.Ipamorelin data sheetThe terse reference: facts, forms, and Pep's verdict.
Send it to me →
No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.